Risk of bias using Cochrane risk-of-bias tool for randomized trials-Kosibord, 2024
If your BMI at the start of the therapy is below a certain threshold and you are not experiencing other risks or conditions, it may not be enough on its own to be eligible for the Bridge Program
The weight loss effect of GLP-1 drug therapy is very beneficial to patients with diabetes
Wanko, GLP-1 medication is a good weight-loss option for patients who: Have a BMI over 30 Have a BMI over 27 with at least one weight-related health problem like diabetes, high blood pressure or high cholesterol Need additional help to increase or maintain weight loss after bariatric surgery To improve your health, a GLP-1 must be part of a more comprehensive approach
Nevertheless, orange urine can also be caused by over consumption of carrots or vitamin B2, while some forms of medication can also lead to orange urine, including sulfasalazine, phenazopyridines, isoniazid and some types of laxative medication
Beginning July 1, 2026, Centers for Medicare & Medicaid Services (CMS) will operate the Medicare GLP-1 Bridge, a short-term demonstration intended to provide eligible Medicare Part D beneficiaries with access to certain GLP-1 medications for weight management